ForSight Robotics is an Israel-based medical-robotics company developing ORYOM (Hebrew for 'daylight'), which it describes as the world's first robotic surgical platform for cataract surgery and other widespread eye diseases. Cataracts are the leading cause of blindness worldwide, and the procedures to treat them are among the most common surgeries on the planet, yet a severe global shortage of trained ophthalmic surgeons leaves hundreds of millions of people without timely access to sight-saving care.
The ORYOM platform aims to change that by combining AI-based algorithms, advanced computer vision and precise micromechanics to assist or perform the extraordinarily delicate maneuvers ophthalmic surgery demands. Eye surgery requires manipulating structures at a sub-millimeter scale with exceptional steadiness, exactly the kind of precision robotics can enhance by augmenting a surgeon's dexterity and removing tremor.
ForSight's broader ambition is access and scalability. By making complex eye procedures more standardized, precise and ultimately more teachable, the company hopes to expand the number of surgeries that can be performed and bring high-quality ophthalmic care to under-served regions, while reducing the physical strain on the limited pool of specialist surgeons.
The company is advancing its platform toward first-in-human clinical trials, a critical step on the path to regulatory clearance and commercialization. In June 2025 ForSight raised a $125 million Series B led by Eclipse, with participation from surgical-robotics pioneer Dr. Fred Moll, the Adani Group, Reiya Ventures and other backers, bringing total funding to roughly $195 million. The capital funds clinical trials, continued development of ORYOM and steps toward commercialization, as ForSight works to make robotic eye surgery a scalable answer to a vast and growing global need.